Published in Gastroenterology on September 14, 2007
Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell (2012) 4.98
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer (2013) 4.02
Role of the microbiota in immunity and inflammation. Cell (2014) 3.43
The microbiome and cancer. Nat Rev Cancer (2013) 2.86
Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One (2009) 2.79
Toll-like receptor-4 inhibits enterocyte proliferation via impaired beta-catenin signaling in necrotizing enterocolitis. Gastroenterology (2009) 2.64
Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol (2010) 2.58
MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med (2010) 2.57
RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis (2008) 2.33
The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J Carcinog (2011) 2.30
S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res (2011) 1.98
Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell (2009) 1.95
Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol (2009) 1.80
Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis (2010) 1.79
Toll-like receptor signaling in cell proliferation and survival. Cytokine (2009) 1.79
The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res (2008) 1.78
MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. Proc Natl Acad Sci U S A (2010) 1.73
Role of Toll-like receptors in gastrointestinal malignancies. Oncogene (2008) 1.69
Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia (2009) 1.66
Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment. Cancer Microenviron (2009) 1.60
TLR9 ligation in pancreatic stellate cells promotes tumorigenesis. J Exp Med (2015) 1.59
High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer (2010) 1.56
Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis (2009) 1.53
Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer (2010) 1.53
Significance of heparanase in cancer and inflammation. Cancer Microenviron (2011) 1.46
Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest (2012) 1.45
An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer. J Exp Med (2010) 1.42
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol (2009) 1.39
Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets (2011) 1.38
TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J (2010) 1.37
Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells. J Clin Invest (2013) 1.37
Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest (2011) 1.32
The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF. Gastroenterology (2008) 1.29
Inflammasomes in intestinal inflammation and cancer. Gastroenterology (2011) 1.28
Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis (2010) 1.28
Toll-like receptors, wound healing, and carcinogenesis. J Mol Med (Berl) (2008) 1.27
Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer. PLoS One (2010) 1.26
Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest (2011) 1.25
Transitions in oral and intestinal microflora composition and innate immune receptor-dependent stimulation during mouse development. Infect Immun (2009) 1.25
The Yin and Yang of Toll-like receptors in cancer. Oncogene (2013) 1.23
S100A8 and S100A9: new insights into their roles in malignancy. J Innate Immun (2011) 1.20
The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterol (2012) 1.20
IKKβ in intestinal mesenchymal cells promotes initiation of colitis-associated cancer. J Exp Med (2015) 1.18
Crucial involvement of tumor-associated neutrophils in the regulation of chronic colitis-associated carcinogenesis in mice. PLoS One (2012) 1.17
Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis (2010) 1.15
The struggle within: microbial influences on colorectal cancer. Inflamm Bowel Dis (2011) 1.15
The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J Transl Med (2010) 1.14
Pathogen recognition receptors, cancer and inflammation in the gut. Curr Opin Pharmacol (2009) 1.14
Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol (2011) 1.14
Tumor suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated carcinoma. Cancer Res (2012) 1.13
Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett (2011) 1.12
Toll-like receptor genes and their association with colon and rectal cancer development and prognosis. Int J Cancer (2011) 1.12
Inflammation and cancer. World J Gastrointest Surg (2012) 1.12
Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system. Br J Cancer (2009) 1.10
TLR4 activates the β-catenin pathway to cause intestinal neoplasia. PLoS One (2013) 1.10
Host-microbial interactions and regulation of intestinal epithelial barrier function: From physiology to pathology. World J Gastrointest Pathophysiol (2012) 1.09
Gastrointestinal malignancy and the microbiome. Gastroenterology (2014) 1.07
TLR4-mediated Cox-2 expression increases intestinal ischemia/reperfusion-induced damage. J Leukoc Biol (2009) 1.06
Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer. Gastroenterology (2011) 1.05
Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis. J Clin Invest (2012) 1.05
Loss of single immunoglobulin interlukin-1 receptor-related molecule leads to enhanced colonic polyposis in Apc(min) mice. Gastroenterology (2010) 1.04
The Role of Inflammation in the Pathogenesis of Colorectal Cancer. Curr Colorectal Cancer Rep (2009) 1.04
Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J Clin Invest (2013) 1.03
Epithelial phosphatidylinositol-3-kinase signaling is required for β-catenin activation and host defense against Citrobacter rodentium infection. Infect Immun (2011) 1.02
MTGR1 is required for tumorigenesis in the murine AOM/DSS colitis-associated carcinoma model. Cancer Res (2011) 1.02
The dual role of inflammation in colon carcinogenesis. Int J Mol Sci (2012) 1.01
The application of Toll like receptors for cancer therapy. Int J Biol Sci (2010) 1.01
Epidermal growth factor receptor inhibits colitis-associated cancer in mice. J Clin Invest (2012) 1.01
The role of pattern recognition receptors in intestinal inflammation. Mucosal Immunol (2013) 1.00
Complement regulates TLR4-mediated inflammatory responses during intestinal ischemia reperfusion. Mol Immunol (2010) 0.99
Toll-like receptors and cancer, particularly oral squamous cell carcinoma. Front Immunol (2014) 0.99
Transactivation of EGFR by LPS induces COX-2 expression in enterocytes. PLoS One (2012) 0.99
American ginseng suppresses Western diet-promoted tumorigenesis in model of inflammation-associated colon cancer: role of EGFR. BMC Complement Altern Med (2011) 0.98
Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis. Innate Immun (2009) 0.97
Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma. PLoS One (2011) 0.97
Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer. J Cell Biochem (2010) 0.96
Toll-like receptors, tissue injury, and tumourigenesis. Mediators Inflamm (2010) 0.96
Microbial imbalance and intestinal pathologies: connections and contributions. Dis Model Mech (2014) 0.96
Inflammatory bowel disease-associated colorectal cancer: proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences. Int J Colorectal Dis (2011) 0.95
Dextran sodium sulfate inhibition of real-time polymerase chain reaction amplification: a poly-A purification solution. Inflamm Bowel Dis (2011) 0.95
Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Onco Targets Ther (2013) 0.94
The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia. BMC Gastroenterol (2010) 0.93
Linking inflammation to tumorigenesis in a mouse model of high-fat-diet-enhanced colon cancer. Cytokine (2013) 0.93
Prohibitin attenuates colitis-associated tumorigenesis in mice by modulating p53 and STAT3 apoptotic responses. Cancer Res (2012) 0.92
Resveratrol enhances cell-mediated immune response to DMBA through TLR4 and prevents DMBA induced cutaneous carcinogenesis. Mol Carcinog (2009) 0.92
Toll-like receptor 4 activation in Barrett's esophagus results in a strong increase in COX-2 expression. J Gastroenterol (2013) 0.92
Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway. Am J Physiol Gastrointest Liver Physiol (2013) 0.92
Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J Inflamm (Lond) (2014) 0.92
Microbes and colorectal cancer: is there a relationship? Curr Oncol (2009) 0.91
IgG expression in human colorectal cancer and its relationship to cancer cell behaviors. PLoS One (2012) 0.91
Tissue expression of Toll-like receptors 2 and 4 in sporadic human colorectal cancer. Cancer Immunol Immunother (2011) 0.91
High-resolution magnetic resonance colonography and dynamic contrast-enhanced magnetic resonance imaging in a murine model of colitis. Magn Reson Med (2010) 0.91
The single IgG IL-1-related receptor controls TLR responses in differentiated human intestinal epithelial cells. J Immunol (2010) 0.90
Expressions of Toll-like receptors 3, 4, 7, and 9 in cervical lesions and their correlation with HPV16 infection in Uighur women. Chin J Cancer (2011) 0.90
Neutrophil infiltration favors colitis-associated tumorigenesis by activating the interleukin-1 (IL-1)/IL-6 axis. Mucosal Immunol (2014) 0.89
Activation of the epidermal growth factor receptor in macrophages regulates cytokine production and experimental colitis. J Immunol (2014) 0.89
Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis. Dig Dis Sci (2010) 0.89
MyD88 and its divergent toll in carcinogenesis. Trends Immunol (2013) 0.88
Upregulation of TLRs and IL-6 as a marker in human colorectal cancer. Int J Mol Sci (2014) 0.87
Colorectal cancer: CRC--all about microbial products and barrier function? Nat Rev Gastroenterol Hepatol (2012) 0.87
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut (2001) 10.07
Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun (1998) 7.86
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 6.15
Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med (2002) 5.70
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science (2005) 5.68
Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun (2000) 5.65
Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol (2004) 5.12
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology (2004) 4.45
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med (2002) 3.47
Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology (2007) 3.39
Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology (2004) 3.11
Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 2.91
Extracellular superoxide production by Enterococcus faecalis promotes chromosomal instability in mammalian cells. Gastroenterology (2006) 2.81
Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology (2002) 2.80
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem (2003) 2.65
Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J Clin Invest (2007) 2.55
TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem (2002) 2.37
Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C. Gastroenterology (2004) 2.33
Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest (2000) 2.27
Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology (2004) 2.23
Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A (1997) 2.12
Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut (1996) 2.06
A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res (2006) 2.02
Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol (2005) 1.98
Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation. Carcinogenesis (2000) 1.95
The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology (2005) 1.83
Sporadic colorectal cancer--role of the commensal microbiota. FEMS Microbiol Lett (2005) 1.82
Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. Cancer Res (2001) 1.78
Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res (1999) 1.68
Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res (2006) 1.68
Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis (2005) 1.65
Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res (2003) 1.48
Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer (2005) 1.39
Type I Helicobacter pylori lipopolysaccharide stimulates toll-like receptor 4 and activates mitogen oxidase 1 in gastric pit cells. Infect Immun (2001) 1.32
Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. J Biol Chem (2004) 1.26
Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res (2005) 1.26
Levels of NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase are reduced in inflammatory bowel disease: evidence for involvement of TNF-alpha. Am J Physiol Gastrointest Liver Physiol (2005) 1.24
Activation of smooth muscle and myenteric plexus cells of jejunum via Toll-like receptor 4. J Cell Physiol (2006) 1.13
Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer. Am J Respir Crit Care Med (2005) 1.09
Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A (2007) 20.60
Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med (2014) 11.07
Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med (2004) 6.42
Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology (2003) 4.64
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA (2004) 4.31
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
Intestinal inflammation and cancer. Gastroenterology (2011) 4.13
Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology (2003) 4.10
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology (2007) 3.39
NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw (2009) 3.37
Use of a patient navigator to increase colorectal cancer screening in an urban neighborhood health clinic. J Urban Health (2005) 3.28
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med (2014) 2.98
Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) (2011) 2.97
Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol (2003) 2.96
Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci (2003) 2.91
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell (2003) 2.71
Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis (2010) 2.62
15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.41
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology (2002) 2.35
Cancers complicating inflammatory bowel disease. N Engl J Med (2015) 2.33
AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.31
Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. Nat Genet (2003) 2.31
Effects of cigarette smoke on the human oral mucosal transcriptome. Cancer Prev Res (Phila) (2010) 2.30
Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem (2002) 2.29
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology (2004) 2.23
Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov (2012) 2.23
Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol (2003) 2.20
Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol (2008) 2.16
Cancer in inflammatory bowel disease. World J Gastroenterol (2008) 2.12
Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila) (2011) 2.09
AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.09
Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res (Phila) (2009) 2.06
Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol (2004) 2.05
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
Successful application of microarray technology to microdissected formalin-fixed, paraffin-embedded tissue. J Mol Diagn (2007) 2.04
Effects of tobacco smoke on gene expression and cellular pathways in a cellular model of oral leukoplakia. Cancer Prev Res (Phila) (2008) 2.04
Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol (2005) 1.98
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology (2003) 1.95
Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol (2005) 1.93
Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria. Gastroenterology (2008) 1.89
Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol (2011) 1.88
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
The effect of HIV and HPV coinfection on cervical COX-2 expression and systemic prostaglandin E2 levels. Cancer Prev Res (Phila) (2011) 1.85
Inflammatory bowel diseases phenotype, C. difficile and NOD2 genotype are associated with shifts in human ileum associated microbial composition. PLoS One (2012) 1.82
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol (2005) 1.79
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology (2006) 1.78
Evaluation of quantitative image analysis criteria for the high-resolution microendoscopic detection of neoplasia in Barrett's esophagus. J Biomed Opt (2010) 1.76
The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease. J Immunol (2008) 1.75
Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology (2004) 1.73
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol (2009) 1.71
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res (Phila) (2008) 1.71
Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. Cancer (2014) 1.71
Appendiceal mucinous cystadenoma is a neoplastic complication of IBD: case-control study of primary appendiceal neoplasms. Inflamm Bowel Dis (2009) 1.69
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
A family of ductile intermetallic compounds. Nat Mater (2003) 1.66
Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia. Cancer Prev Res (Phila) (2012) 1.66
Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol (2009) 1.66
Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res (2010) 1.66
Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst (2007) 1.65
Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. Clin Cancer Res (2013) 1.65
Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials (2007) 1.62
Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst (2014) 1.61
Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem (2003) 1.60
Colon cancer, version 3.2014. J Natl Compr Canc Netw (2014) 1.59
Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer. Gastroenterology (2004) 1.59
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res (2002) 1.59
GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science (2013) 1.58
Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res (2011) 1.58
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 1.57